← FDA DRUG APPROVALS

FDA ANDA · ANDA215709

FLUORESCEIN

Sponsor: NEXUS

APPLICATION
ANDA215709
TYPE
ANDA
ORIGINAL APPROVAL
2023-09-25
LATEST ACTION
2023-09-25
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription, Discontinued

Products

FLUORESCEIN SODIUMPrescription
FLUORESCEIN SODIUM EQ 500MG BASE/5ML (EQ 100MG BASE/ML) · INJECTABLE · INTRAVENOUS
FLUORESCEIN SODIUMDiscontinued
FLUORESCEIN SODIUM EQ 500MG BASE/2ML (EQ 250MG BASE/ML) · INJECTABLE · INTRAVENOUS

Approval history

2023-09-25UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →